Novo Nordisk's Danish Buyback Meets a Chinese Hurdle: A Stock Caught Between Conviction and Competition

Novo Nordisk's $1.2B buyback and China filing contrast with Deutsche Bank's Sell rating; JPMorgan raises target. GLP-1 race heats up.

The arithmetic of Novo Nordisk's share repurchase program tells a story of quiet confidence. By August 21, the Danish drugmaker had bought back nearly 30 million B-shares at an average price of 280.34 kroner, deploying over 8.3 billion kroner of the 15 billion kroner program. That is a substantial commitment, executed during a stretch when the stock has struggled to find its footing.

Yet the buyback is only half the picture. The same week brought a sharp downgrade from Deutsche Bank, which moved the stock to Sell from Hold and trimmed its price target to 265 kroner from 290 kroner. The bank cited reduced medium-term revenue estimates following disappointing Ziltivekimab data — the failed Phase 3 trial for the heart drug that rattled investors back in late July. It is the harshest rating any major house currently assigns the stock.

JPMorgan, by contrast, lifted its price target to 275 kroner from 250 kroner on Monday, keeping a Neutral stance. The bank's reasoning: stronger Ozempic expectations, limited generic erosion, and favorable US gross-profit adjustments in the second quarter. JPMorgan also raised its 2026 revenue forecast by 5 percent. Two respected institutions, two nearly opposite conclusions — a tidy illustration of just how divided Wall Street has become on Novo's trajectory.

A Narrow Opening in Beijing

The more constructive news came out of China, where the National Medical Products Administration (NMPA) has accepted Novo's marketing application for oral Wegovy. That is a meaningful procedural step, but not a green light. A market of China's scale could eventually contribute substantially to revenue, yet the timeline to actual market authorization remains uncertain. The filing positions Novo for a potential entry, but it does not yet move the needle on the balance sheet.

Timing, however, is everything in this race. Eli Lilly submitted its competing oral candidate, Orforglipron, in China as early as late 2025, giving the US rival a head start in a country where estimates suggest more than 65 percent of the population could be overweight by 2030. The strategic stakes are enormous: whoever establishes a foothold early in China secures one of the largest growth markets for GLP-1 therapies anywhere in the world.

The stock's recent performance reflects that competitive tension. The shares closed Friday at 39.41 euros, down 0.6 percent on the day, and sit roughly 28 percent below their 52-week high of 54.86 euros reached in January. That gap captures investor unease about Novo's competitive positioning — a discount that could either narrow or widen depending on how the Chinese approval process unfolds.

Defending the Franchise on Multiple Fronts

Beyond the regulatory filing, Novo is actively protecting its intellectual property. A court in The Hague issued an injunction against Ceban Ziekenhuisfarmacie, which had been distributing a compounded semaglutide nasal spray that infringed Novo's rights. Notably, no semaglutide nasal spray has regulatory approval anywhere in the world — meaning Novo is pursuing infringers even before a legal market exists for the product. It is a display of vigilance, though it does little to alter the fundamental competitive landscape.

The company is also exploring a partnership with Vivani Medical on an implant that would automatically administer Wegovy — a potential differentiator against Lilly. Both projects remain in early-to-mid development stages, with no decision yet from Chinese regulators.

The Bull and Bear Case in Numbers

The optimistic scenario rests on several pillars. If the NMPA reviews oral Wegovy efficiently, Novo could potentially overtake Lilly despite filing later, particularly if its regulatory profile proves simpler or clinical advantages emerge. The Vivani implant could serve as an additional differentiator if it proves practical in real-world use.

Fundamentals lend some support to the bull case. Novo Nordisk carries a net margin of 35.36 percent and a price-to-earnings ratio of roughly 11 — notably cheaper than its primary competitor. A consensus analyst price target of 64.94 US dollars implies upside of more than 42 percent from recent levels. The company's generics strategy in South Africa, where it offers its own product at around 15 percent less, shows a willingness to respond to pricing pressure rather than simply absorb it.

The bear case, however, is substantial. Lilly already generates roughly two-thirds of its revenue from GLP-1 products, became the first pharmaceutical company to reach a market capitalization of one trillion US dollars, and recently secured FDA approval for Mounjaro to reduce heart attack and stroke risk — an indication expansion Novo has yet to match. The patent cliff looms as well: Novo derives 77 percent of its 2025 revenue from products whose patent protection expires by 2033, with Ozempic's US exclusivity ending in the early 2030s. Generic competition is already emerging, including in South Africa, where the first generic GLP-1 product is available and 13 additional applications are under review.

Clinical setbacks have compounded the pressure. The failed cardiovascular approach Novo supported has opened a door for Novartis, which is now advancing its own antibody candidate into Phase 3.

What Comes Next

The immediate catalyst is the NMPA's decision on oral Wegovy, though no timeline has been announced. Until then, the stock — with a relative strength index of 43, neither overbought nor oversold — remains a barometer of the unresolved competitive question at the heart of the GLP-1 race.

The buyback signals management's belief in the stock's fair value, and the August confirmation of raised full-year guidance on revenue and operating profit at constant exchange rates underscores that operations remain solid. Yet since that earnings release roughly a month ago, the shares have gained just 1.8 percent — a modest return for a company delivering on its operational commitments.

Whether the repurchase program can ultimately refute Deutsche Bank's Sell rating depends largely on factors beyond management's control, most notably how quickly Eli Lilly continues to gain market share. The buyback stabilizes; it does not yet convince. For now, the balance between discipline and doubt remains finely poised, with the Chinese regulatory decision likely to tip the scales in one direction or the other.